Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1521 - Incremental cost-effectiveness analysis of hepatic metastasectomy in patients with advanced colon cancer and liver metastasis


09 Oct 2016


Poster display


Sudpreeda Chainitikun


Annals of Oncology (2016) 27 (6): 351-358. 10.1093/annonc/mdw377


S. Chainitikun

Author affiliations

  • Medical Oncology, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH


Abstract 1521


Colorectal cancer with liver metastasis is a potentially curable malignancy. Multidisciplinary treatment including hepatic tumor resection provides 20-40% 5 year survival rate. However, the utility of hepatic resection for liver metastases in colorectal cancer is still debatable. Liver metastasectomy requires specialized centers having expertise, resources, and awareness which consume significant amount of hospital budgets. We aimed to evaluate the cost-effectiveness of hepatic metastasectomy in patients with advanced colon cancer with liver metastasis.


Medical records of advanced colon cancer patients with liver metastasis only who treated at the King Chulalongkorn Memorial Hospital during January 2007 to 31 December 2010 were reviewed. The study endpoint is to compare the cost per life-year gained in term of incremental cost-effectiveness ratio (ICER) between with or without hepatic metastasectomy by the decision model. Data regarding site of primary tumor, characteristics of liver metastases, treatment strategies, chemotherapy regimens, biologic agents, complications, health coverage and survival data were collected and analyzed.


There were 34 patients in liver surgery group and 28 patients in without surgery group. There was significantly longer median survival time in the surgery group vs no surgery, 42.22 vs 18.04 months, respectively (HR = 23.3, P 


Under the routine clinical service, hepatic metastasectomy is a cost-effective option for patients with colon cancer with liver only metastasis in the tertiary care hospital setting.

Clinical trial identification


Legal entity responsible for the study

Medical Oncology Department, Faculty of Medicine, Chulalongkorn University




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings